Effects of exenatide on urinary albumin in overweight/obese patients with T2DM: a randomized clinical trial.

Kang C, Qiao Q, Tong Q, Bai Q, Huang C, Fan R, Wang H, Kaliannan K, Wang J, Xu J

Scientific reports8 Oct 2021Cited by 8 (Europe PMC)

PMID34625598PMCIDPMC8501012DOI10.1038/s41598-021-99527-yPepBankPUB-34625598

Summary

In this study, we investigated the effect of exenatide (EXE), a glucagon-like peptide (GLP)-1 receptor agonist, on kidney function, obesity indices, and glucose control in overweight/obese patients with type 2 diabetes mellitus (T2DM). A total of 159 overweight/obese patients with T2DM were randomized to the EXE group or insulin glargine (GLAR) control group for a total treatment period of 24 weeks. EXE intervention significantly reduced the urine albumin concentration (UAC) at week 12 and 24 endpoints (P < 0.001 at week 12 and 24). The levels of the anthropometric, glucose and lipid parameters (TG and HDL-c), and inflammation biomarkers (CRP and TNF-α) in the EXE group were improved at 12 weeks or 24 weeks, respectively. Meanwhile, a comparison between two groups showed significant changes in anthropometric parameters, glucose parameters, lipid parameters (TG and HDL-c), and Inflammation biomarkers (CRP, IL-6, and TNF-α). Serum fibroblast growth factor 21 (FGF21) was increased in the EXE group (P = 0.005) at week 24, and the change was significantly improved compared with GLAR group (P = 0.003). Correlation network analysis showed that FGF21 had a more central role in improving metabolism in the EXE group, and the change of FGF 21 was significantly negatively correlated with UAC at week 12 and week 24, respectively (r = - 0.297, P = 0.010; r = - 0.294, P = 0.012). Our results showed that EXE could help patients improve UAC, glycemic levels, and inflammatory biomarkers after a follow-up period of 24 weeks intervention. These EXE effects may be partly mediated by FGF 21, indicating that EXE is an effective and safe way to control albuminuria in overweight/obese patients with T2DM.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In overweight or obese patients with diabetes, exenatide and glargine differed in anthropometric, glucose, lipid and inflammatory parameters.
In plain wordsIn overweight or obese patients with diabetes, several metabolic and inflammatory measures differed between exenatide and glargine.
Peptide
Exenatide (exendin-4)
Outcome
Direction not reportedAnthropometric, glucose, lipid and inflammatory contrasts
Study
n = 159
Comparator
Insulin glargine
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Meanwhile, a comparison between two groups showed significant changes in anthropometric parameters, glucose parameters, lipid parameters (TG and HDL-c), and Inflammation biomarkers (CRP, IL-6, and TNF-α).
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 159 overweight/obese patients with T2DM were randomized to the EXE group or insulin glargine (GLAR) control group for a total treatment period of 24 weeks.
Show in the study text Report a problemFND-3462559803
02HumanRandomized controlled trialMechanism
In overweight or obese patients with diabetes, exenatide increased serum FGF21 more than glargine at week 24.
In plain wordsIn overweight or obese patients with diabetes, exenatide increased serum FGF21 more than glargine.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseSerum FGF21 between-group change
Study
n = 159
Comparator
Insulin glargine
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Serum fibroblast growth factor 21 (FGF21) was increased in the EXE group (P = 0.005) at week 24, and the change was significantly improved compared with GLAR group (P = 0.003).
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 159 overweight/obese patients with T2DM were randomized to the EXE group or insulin glargine (GLAR) control group for a total treatment period of 24 weeks.
Show in the study text Report a problemFND-3462559805
03HumanRandomized controlled trialEfficacy outcome
In overweight or obese patients with diabetes, exenatide reduced urine albumin at weeks 12 and 24.
In plain wordsIn overweight or obese patients with diabetes, urine albumin decreased during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseUrine albumin concentration
Study
n: not reported in source
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
EXE intervention significantly reduced the urine albumin concentration (UAC) at week 12 and 24 endpoints (P < 0.001 at week 12 and 24).
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 159 overweight/obese patients with T2DM were randomized to the EXE group or insulin glargine (GLAR) control group for a total treatment period of 24 weeks.
Show in the study text Report a problemFND-3462559801
04HumanRandomized controlled trialEfficacy outcome
In overweight or obese patients with diabetes, anthropometric, glucose, lipid and inflammatory parameters improved during exenatide treatment.
In plain wordsIn overweight or obese patients with diabetes, several metabolic and inflammatory measures improved during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
MixedAnthropometric, glucose, lipid and inflammatory parameters
Study
n: not reported in source
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
The levels of the anthropometric, glucose and lipid parameters (TG and HDL-c), and inflammation biomarkers (CRP and TNF-α) in the EXE group were improved at 12 weeks or 24 weeks, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 159 overweight/obese patients with T2DM were randomized to the EXE group or insulin glargine (GLAR) control group for a total treatment period of 24 weeks.
Show in the study text Report a problemFND-3462559802
05HumanObservational studyMechanism
In exenatide-treated patients with diabetes, network analysis identified a more central metabolic role for FGF21.
In plain wordsIn exenatide-treated patients with diabetes, network analysis identified FGF21 as a central metabolic marker.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableFGF21 network centrality
Study
n: not reported in source
Outcome group
Receptor activity and mechanism · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Correlation network analysis showed that FGF21 had a more central role in improving metabolism in the EXE group
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 159 overweight/obese patients with T2DM were randomized to the EXE group or insulin glargine (GLAR) control group for a total treatment period of 24 weeks.
Show in the study text Report a problemFND-3462559806
06HumanObservational studyMechanism
In overweight or obese patients with type 2 diabetes, the change in FGF21 correlated negatively with urine albumin concentration at weeks 12 and 24.
In plain wordsIn overweight or obese patients with type 2 diabetes, FGF21 changes were linked to lower urine albumin at weeks 12 and 24.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseFGF21 change association with urine albumin
Study
n: not reported in source
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Measurements
Correlation of FGF21 change with UAC (week 12)
−0.297 r
week 12
Correlation of FGF21 change with UAC (week 24)
−0.294 r
week 24
Source sentences
Summary
the change of FGF 21 was significantly negatively correlated with UAC at week 12 and week 24, respectively (r = - 0.297, P = 0.010; r = - 0.294, P = 0.012)
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 159 overweight/obese patients with T2DM were randomized to the EXE group or insulin glargine (GLAR) control group for a total treatment period of 24 weeks.
Show in the study text Report a problemFND-3462559807

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.